BRPI0406800A - Peptìdio dimerizado - Google Patents

Peptìdio dimerizado

Info

Publication number
BRPI0406800A
BRPI0406800A BR0406800-9A BRPI0406800A BRPI0406800A BR PI0406800 A BRPI0406800 A BR PI0406800A BR PI0406800 A BRPI0406800 A BR PI0406800A BR PI0406800 A BRPI0406800 A BR PI0406800A
Authority
BR
Brazil
Prior art keywords
peptide
dimerized
tumor antigen
dimerized peptide
peptidia
Prior art date
Application number
BR0406800-9A
Other languages
English (en)
Inventor
Haruo Sugiyama
Hideo Takasu
Fumio Samizo
Original Assignee
Haruo Sugiyama
Chugai Pharmaceutical Co Ltd
Sumitomo Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Haruo Sugiyama, Chugai Pharmaceutical Co Ltd, Sumitomo Pharma filed Critical Haruo Sugiyama
Publication of BRPI0406800A publication Critical patent/BRPI0406800A/pt
Publication of BRPI0406800A8 publication Critical patent/BRPI0406800A8/pt
Publication of BRPI0406800B1 publication Critical patent/BRPI0406800B1/pt
Publication of BRPI0406800B8 publication Critical patent/BRPI0406800B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

"PEPTìDIO DIMERIZADO". A presente invenção refere-se a um novo peptídio antígeno de tumor e a vacina para câncer do mesmo, de modo específico um dímero de peptídio, no qual dois monómeros de peptídio que consistem em 7 a 30 aminoácidos que incluem, pelo menos um resíduo de cisteína e sendo capazes de produzir um peptídio antígeno de tumor estão ligados um com o outro através de uma ligação de dissulfeto.
BRPI0406800A 2003-01-15 2004-01-15 "dímero de peptídeo, composição farmacêutica contendo o mesmo e seu uso BRPI0406800B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003-007122 2003-01-15
JP2003007122 2003-01-15
PCT/JP2004/000254 WO2004063217A1 (ja) 2003-01-15 2004-01-15 二量体化ペプチド

Publications (4)

Publication Number Publication Date
BRPI0406800A true BRPI0406800A (pt) 2006-01-17
BRPI0406800A8 BRPI0406800A8 (pt) 2016-11-01
BRPI0406800B1 BRPI0406800B1 (pt) 2020-08-11
BRPI0406800B8 BRPI0406800B8 (pt) 2021-05-25

Family

ID=32709100

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0406800A BRPI0406800B8 (pt) 2003-01-15 2004-01-15 "dímero de peptídeo, composição farmacêutica contendo o mesmo e seu uso

Country Status (12)

Country Link
US (2) US20060217297A1 (pt)
EP (2) EP2154145B1 (pt)
JP (2) JP4498274B2 (pt)
KR (2) KR20120054644A (pt)
CN (2) CN101851275A (pt)
AT (1) ATE444969T1 (pt)
AU (1) AU2004204031B2 (pt)
BR (1) BRPI0406800B8 (pt)
CA (1) CA2513701C (pt)
DE (1) DE602004023476D1 (pt)
ES (1) ES2332590T3 (pt)
WO (1) WO2004063217A1 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4932199A (en) * 1998-07-31 2000-02-21 Haruo Sugiyama Cancer antigens based on tumor suppressor gene wt1 product
EP1371664B1 (en) * 2001-03-22 2008-01-09 International Institute of Cancer Immunology, Inc. Wti modified peptide
CA2448109A1 (en) * 2001-05-25 2002-12-05 Thomas Jefferson University Alternative splice forms of proteins as basis for multiple therapeutic modalities
WO2004024175A1 (ja) * 2002-09-12 2004-03-25 Haruo Sugiyama 癌抗原ペプチド製剤
KR101213015B1 (ko) 2003-11-05 2012-12-26 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 Ｗｔ１ 로부터 유도된 ｈｌａ-ｄｒ 결합성 항원 펩티드
PT1731605E (pt) * 2004-03-31 2010-04-14 Int Inst Cancer Immunology Inc Péptidos antigénicos de cancro derivados de wt1
ES2523172T3 (es) * 2005-02-04 2014-11-21 Survac Aps Vacuna de péptido de survivina
CA2631292C (en) 2005-11-30 2014-05-06 International Institute Of Cancer Immunology, Inc. Derivatised wt1 cancer antigen peptides and their use
AU2007218649B2 (en) 2006-02-22 2013-01-10 International Institute Of Cancer Immunology, Inc. HLA-A*3303-restricted WT1 peptide and pharmaceutical composition comprising the same
ZA200807027B (en) * 2006-02-23 2009-12-30 Fibrex Medical Res & Dev Gmbh Peptides and peptide derivatives, the production thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
EP2341142B8 (en) 2006-12-28 2015-01-14 International Institute of Cancer Immunology, Inc. HLA-A*1101-restricted WT1 peptide and pharmaceutical composition comprising same
BRPI0808084A2 (pt) 2007-02-27 2014-07-22 Int Inst Cancer Immunology Inc Método para ativação de células t auxiliadoras e composição para uso no método.
DK2193142T3 (da) * 2007-08-30 2015-04-20 Curedm Group Holdings Llc Præparater og fremgangsmåder til anvendelse af pro-øcellepeptider og analoger dertil
KR20140009168A (ko) 2010-10-05 2014-01-22 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 헬퍼 ｔ 세포의 활성화 방법
EP2646459B1 (en) 2010-12-02 2020-01-08 Bionor Immuno AS Peptide scaffold design
MX2013007146A (es) * 2010-12-23 2013-11-01 Intercell Austria Ag Agentes de proteina f/i de membrana externa (oprf/i) y su uso en pacientes hospitalizados y otros pacientes.
JP6294076B2 (ja) 2011-01-06 2018-03-14 ビオノール イミュノ エーエスＢｉｏｎｏｒ Ｉｍｍｕｎｏ Ａｓ 多量体ペプチド
JP6082901B2 (ja) * 2011-01-31 2017-02-22 オリンパス株式会社 ワクチン・アジュバント
JP6163486B2 (ja) 2012-07-02 2017-07-12 大日本住友製薬株式会社 癌抗原ペプチド経皮剤
SG10201705028WA (en) 2012-12-17 2017-07-28 Otsuka Pharma Co Ltd Method for activating helper t cell
EP2974734B1 (en) 2013-03-12 2018-10-10 Sumitomo Dainippon Pharma Co., Ltd. Liquid aqueous composition
SG11201507883SA (en) * 2013-03-29 2015-10-29 Sumitomo Dainippon Pharma Co Ltd Wt1-antigen peptide conjugate vaccine
WO2014157704A1 (ja) 2013-03-29 2014-10-02 大日本住友製薬株式会社 Ｅｒａｐ１によるトリミング機能をきっかけとしたコンジュゲートワクチン
KR20160063349A (ko) 2013-10-17 2016-06-03 서울대학교산학협력단 알파나선형 세포 투과 펩타이드 다합체，이의 제조방법 및 그 용도
ES2916834T3 (es) * 2014-09-27 2022-07-06 Sumitomo Pharma Co Ltd Composición farmacéutica para inyección
JP6671141B2 (ja) * 2014-10-21 2020-03-25 大日本住友製薬株式会社 懸濁液剤
CN107921106B (zh) * 2015-05-20 2023-09-08 住友制药株式会社 Wt1抗原肽和免疫调节剂的组合用途
ES3038398T3 (en) 2015-07-14 2025-10-13 Yeda Res & Dev Peptide combinations for use in the diagnosis of schizophrenia
US12383608B2 (en) 2016-11-30 2025-08-12 Sumitomo Pharma Co., Ltd. WT1 helper peptides and combinations of WT1 helper peptide and conjugate of cancer antigen peptides
US20200368338A1 (en) * 2017-12-27 2020-11-26 Sumitomo Dainippon Pharma Co., Ltd. Conjugate of wt1-derived peptides and composition comprising the same
US12233130B2 (en) 2022-12-22 2025-02-25 Defence Therapeutics Inc. Covalently-modified steroid acid-peptides having enhanced stability and/or biological activity

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6034235A (en) * 1995-06-01 2000-03-07 Tadamitsu Kishimoto Growth inhibitor for leukemia cell comprising antisense oligonucleotide derivative to wilms tumor gene (WT1)
JP3060287B2 (ja) 1995-10-09 2000-07-10 参天製薬株式会社 アパファントを主薬とする水性点眼剤
AU4932199A (en) 1998-07-31 2000-02-21 Haruo Sugiyama Cancer antigens based on tumor suppressor gene wt1 product
US7063854B1 (en) * 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
AR021849A1 (es) * 1998-09-30 2002-08-07 Corixa Corp Composiciones y metodos para la inmunoterapia especifica de wt1
GB9823897D0 (en) * 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
WO2002047474A1 (en) 2000-12-13 2002-06-20 Sumitomo Pharmaceuticals Company, Limited Transgenic animal expressing hla-a24 and utilization thereof
EP1371664B1 (en) * 2001-03-22 2008-01-09 International Institute of Cancer Immunology, Inc. Wti modified peptide
JP5230891B2 (ja) * 2001-09-28 2013-07-10 株式会社癌免疫研究所 抗原特異的ｔ細胞の新規な誘導方法
US20050002951A1 (en) * 2001-09-28 2005-01-06 Haruo Sugiyama Novel method of inducing antigen-specific t cells
WO2003106682A1 (ja) * 2002-06-12 2003-12-24 中外製薬株式会社 Ｈｌａ−ａ２４拘束性癌抗原ペプチド
KR101213015B1 (ko) 2003-11-05 2012-12-26 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 Ｗｔ１ 로부터 유도된 ｈｌａ-ｄｒ 결합성 항원 펩티드
PT1731605E (pt) 2004-03-31 2010-04-14 Int Inst Cancer Immunology Inc Péptidos antigénicos de cancro derivados de wt1

Also Published As

Publication number Publication date
KR20120054644A (ko) 2012-05-30
CA2513701A1 (en) 2004-07-29
KR20050098863A (ko) 2005-10-12
DE602004023476D1 (de) 2009-11-19
EP1584627A1 (en) 2005-10-12
ES2332590T3 (es) 2010-02-09
US8242084B2 (en) 2012-08-14
CA2513701C (en) 2013-06-18
EP2154145A2 (en) 2010-02-17
JP2010047603A (ja) 2010-03-04
JP4498274B2 (ja) 2010-07-07
CN1756763A (zh) 2006-04-05
EP1584627B1 (en) 2009-10-07
BRPI0406800B1 (pt) 2020-08-11
EP2154145B1 (en) 2013-04-24
CN1756763B (zh) 2010-05-26
BRPI0406800A8 (pt) 2016-11-01
BRPI0406800B8 (pt) 2021-05-25
CN101851275A (zh) 2010-10-06
EP2154145A3 (en) 2010-05-19
JPWO2004063217A1 (ja) 2006-06-01
JP4926231B2 (ja) 2012-05-09
US20060217297A1 (en) 2006-09-28
US20100292164A1 (en) 2010-11-18
AU2004204031B2 (en) 2010-03-04
AU2004204031A1 (en) 2004-07-29
WO2004063217A1 (ja) 2004-07-29
EP1584627A4 (en) 2006-03-15
ATE444969T1 (de) 2009-10-15
HK1081975A1 (en) 2006-05-26
HK1141539A1 (en) 2010-11-12
KR101399678B1 (ko) 2014-05-27

Similar Documents

Publication Publication Date Title
BRPI0406800A (pt) Peptìdio dimerizado
BR0211623A (pt) Agentes de contraste alvos multiméricos com base em peptìdeo
BRPI0414497A (pt) análogos de talidomida
CY1118037T1 (el) Αντισωματα εναντι του αβητα και h χρηση τους
BR0305074A (pt) Composições cosméticas com alta afinidade
MX2009007008A (es) Peptido wt1 restringido a hla-a*1101 y composicion farmaceutica que comprende el mismo.
CY1113850T1 (el) Νεα παραγωγα ινσουλινης
CY1117387T1 (el) ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ
CR8444A (es) Immunogenic peptide carrier conjugates and methods of producing same
DK1423419T3 (da) Hybrid- og tandemekspression af Neisseria-proteiner
AR033978A1 (es) Molecula de anticuerpo con especificidad para factor de necrosis tumoral alfa humano y usos de las mismas
ATE536188T1 (de) Fcgammariib-spezifische antikörper und verfahren zur verwendung davon
ATE495739T1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
PE20081634A1 (es) Fab ab pegilado
GT200300072AA (es) Aminoacidos con afinidad por la proteina alfa2delta (solicitud fraccionaria
BR0306715A (pt) Métodos para diagnóstico e tratamento de tumores
BR0008916A (pt) Composiçao nutricional projetada para maturação gastrointestinal especìfica em mamìferos prematuros
DK1873166T3 (da) Forbedrede sgp 130Fc-dimerer
UY30984A1 (es) Proteinas de fusion de formula m-a para degradar péptidos beta amiloides, composiciones en base a ella, preparacion y aplicaciones.
BRPI0505302A (pt) processo de toner
BR0315864A (pt) Composições e processos para a modificação efeitos tóxicos de compostos proteináceos
PE20050962A1 (es) Anticuerpos completamente humanos contra 4-1bb humano
ATE495247T1 (de) Chromoprotein und fluoroproteine
DE69931482D1 (de) Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
ATE532793T1 (de) Verfahren zur herstellung von molekülen mit verminderter immunogenität

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25D Requested change of name of applicant approved

Owner name: CHUGAI SEIYAKU KABUSHIKI KAISHA (CHUGAI PHARMACEUT

B25A Requested transfer of rights approved

Owner name: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/08/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/01/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25D Requested change of name of applicant approved

Owner name: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC. (JP) ; SUMITOMO PHARMA CO., LTD. (JP)

B25G Requested change of headquarter approved

Owner name: INTERNATIONAL INSTITUTE OF CANCER IMMUNOLOGY, INC. (JP) ; SUMITOMO PHARMA CO., LTD. (JP)

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2809 DE 05-11-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.